BioNTech-Pfizer said their vaccine showed 100% efficacy against the coronavirus in children aged 12 to 15, as they eye approval for adolescents to get the jabs before the next school year.
Phase 3 trials carried out on 2,260 adolescents in the United States "demonstrated 100% efficacy and robust antibody responses", the companies said in a statement. "We plan to submit these data to (US regulator) FDA as a proposed amendment to our Emergency Use Authorisation in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year," said Pfizer chief executive Albert Bourla.